Gastrointestinal Cancer | Specialty

FDA Approval in HER2+ Breast Cancer, Priority Review in NSCLC, and More

February 1st 2020

Review Period Extended in GIST, Disappointing Findings in Lung Cancer, and More

February 1st 2020

Treating Unresectable HCC in the Community

February 1st 2020

Sequencing With I-O Combinations in Unresectable HCC

February 1st 2020

Emerging I-O Combination Trials in Unresectable HCC

February 1st 2020

IMbrave150 in Unresectable HCC

February 1st 2020

Immunotherapy in Unresectable HCC

February 1st 2020

Challenges With Novel Treatment Strategies

February 1st 2020

The COSMIC-312 Phase III and Other Notable Trials

February 1st 2020

IMbrave150 Phase III Design, Results, and Practical Implications

February 1st 2020

The Impact of Liver Pathobiology on HCC Treatment Approach

February 1st 2020

Japanese Approval Sought for Cabozantinib in Advanced HCC

January 30th 2020

A new drug application has been filed with the Japanese Ministry of Health, Labor and Welfare for manufacturing and marketing approval of cabozantinib for the treatment of patients with unresectable hepatocellular carcinoma following progression on prior systemic therapy.

QoL Superior With Atezolizumab/Bevacizumab Versus Sorafenib in Frontline HCC

January 28th 2020

Analysis of patient-reported outcomes from the phase III IMbrave 150 study showed meaningful benefits in quality of life, functioning, and key symptoms with atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.

Trastuzumab Deruxtecan Improves Survival in Heavily Pretreated HER2+ Gastric/GEJ Cancer

January 28th 2020

Trastuzumab deruxtecan (Enhertu) improved overall survival versus chemotherapy in patients with heavily pretreated unresectable or metastatic HER2-positive gastric or gastroesophageal junction cancer.

Triplet and Doublet Regimens Outperform Standard of Care on Survival, QoL in BRAF+ CRC

January 27th 2020

Encorafenib plus cetuximab with or without binimetinib demonstrated longer maintenance of quality of life on patient-reported assessments over current standard of care in the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer.

FDA Approval Sought for Frontline Atezolizumab Plus Bevacizumab in HCC

January 27th 2020

A supplemental biologics license application has been submitted to the FDA for the combination of atezolizumab and bevacizumab for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCC

January 27th 2020

Augusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.

Dr. O'Reilly on Veliparib/Chemotherapy Triplet in Germline BRCA/PALB2+ Pancreatic Cancer

January 27th 2020

Eileen M. O’Reilly, MD, discusses the randomized phase II trial of gemcitabine and cisplatin versus gemcitabine and cisplatin and veliparib in patients with pancreas adenocarcinoma harboring a known germline BRCA or PALB2 mutation, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC

January 27th 2020

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

Second-Line Ramucirumab Improves OS in AFP-Elevated HCC, Regardless of Disease Stage

January 27th 2020

Ramucirumab as second-line therapy after sorafenib induces improved overall survival compared with placebo, irrespective of Barcelona Clinic Liver Cancer stage, in patients with intermediate-stage hepatocellular carcinoma and an elevated baseline level of alpha fetoprotein.